Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals

Čájet eará veršuvnnaid (1)

<p style="text-align:justify;"> <b>Background:</b> Circumsporozoite protein (CS) is the antigenic target for RTS,S, the most advanced malaria vaccine to date. Heterologous prime-boost with the viral vectors simian adenovirus 63 (ChAd63)-modified vaccinia virus Ankara (MV...

Bibliográfalaš dieđut
Váldodahkkit:	Hodgson, SH, Ewer, KJ, Bliss, CM, Edwards, NJ, Rampling, T, Anagnostou, NA, De Barra, E, Havelock, T, Bowyer, G, Poulton, ID, De Cassan, S, Longley, R, Illingworth, JJ, Douglas, AD, Mange, PB, Collins, KA, Roberts, R, Gerry, S, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Sinden, RE, Gilbert, SC, Bejon, P, Lawrie, AM, Nicosia, A, Faust, SN, Hill, AV
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	Oxford University Press 2014

Geahča maid

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
Dahkki: Hodgson, S, et al.
Almmustuhtton: (2014)

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans
Dahkki: Sheehy, S, et al.
Almmustuhtton: (2012)

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
Dahkki: Sheehy, S, et al.
Almmustuhtton: (2012)

Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with ChAd-MVA vectored vaccines expressing ME-TRAP
Dahkki: Rampling, T, et al.
Almmustuhtton: (2016)

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
Dahkki: Kimani, D, et al.
Almmustuhtton: (2014)

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
Dahkki: De Barra, E, et al.
Almmustuhtton: (2014)

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
Dahkki: Ewer, K, et al.
Almmustuhtton: (2013)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Dahkki: Elias, S, et al.
Almmustuhtton: (2014)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Dahkki: Ogwang, C, et al.
Almmustuhtton: (2013)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure
Dahkki: Biswas, S, et al.
Almmustuhtton: (2014)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
Dahkki: Tiono, AB, et al.
Almmustuhtton: (2018)

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
Dahkki: Eoghan de Barra, et al.
Almmustuhtton: (2014-01-01)

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
Dahkki: Bliss, C, et al.
Almmustuhtton: (2018)

Safety and Efficacy of Novel Malaria Vaccine Regimens of RTS,S/AS01B alone, or with Concomitant ChAd63-MVA Vectored Vaccines Expressing ME-TRAP
Dahkki: Rampling, T, et al.
Almmustuhtton: (2018)

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
Dahkki: Sheehy, S, et al.
Almmustuhtton: (2011)

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Dahkki: Sheehy, S, et al.
Almmustuhtton: (2011)

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
Dahkki: Sumi Biswas, et al.
Almmustuhtton: (2014-01-01)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.
Dahkki: Alfred B Tiono, et al.
Almmustuhtton: (2018-01-01)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
Dahkki: Morter, R, et al.
Almmustuhtton: (2022)

Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults
Dahkki: Rampling, T, et al.
Almmustuhtton: (2015)

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Dahkki: Sheehy, S, et al.
Almmustuhtton: (2012)

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Dahkki: Caroline Ogwang, et al.
Almmustuhtton: (2013-01-01)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants
Dahkki: Bliss, C, et al.
Almmustuhtton: (2016)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
Dahkki: Richard Morter, et al.
Almmustuhtton: (2022-12-01)

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo
Dahkki: Ewer, K, et al.
Almmustuhtton: (2018)

Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.
Dahkki: Hodgson, S, et al.
Almmustuhtton: (2014)

Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein.
Dahkki: Marcela Parra, et al.
Almmustuhtton: (2015-01-01)

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
Dahkki: Dunachie, S, et al.
Almmustuhtton: (2006)

Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein.
Dahkki: Plebanski, M, et al.
Almmustuhtton: (1997)

Circumsporozoite Surface Protein-based malaria vaccines: a review
Dahkki: Maria Edilene Martins de Almeida, et al.
Almmustuhtton: (2021-01-01)

Malaria oocysts require circumsporozoite protein to evade mosquito immunity
Dahkki: Feng Zhu, et al.
Almmustuhtton: (2022-06-01)

Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial
Dahkki: de Graaf, H, et al.
Almmustuhtton: (2021)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Dahkki: Mensah, V, et al.
Almmustuhtton: (2016)

Stratification and Adaptation of Malaria Control Interventions in Chad
Dahkki: Mahamat Idriss Djaskano, et al.
Almmustuhtton: (2023-09-01)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
Dahkki: O'Hara, G, et al.
Almmustuhtton: (2012)

Antibody Targets and Properties for Complement-Fixation Against the Circumsporozoite Protein in Malaria Immunity
Dahkki: Liriye Kurtovic, et al.
Almmustuhtton: (2021-12-01)

Generation of multivalent recombinant MVA vaccines for malaria
Dahkki: Orubu, T
Almmustuhtton: (2012)

An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein
Dahkki: Lucie Jelínková, et al.
Almmustuhtton: (2021-01-01)

Sterile protection against malaria is independent of immune responses to the circumsporozoite protein.
Dahkki: Anne Charlotte Grüner, et al.
Almmustuhtton: (2007-12-01)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Dahkki: Victorine A Mensah, et al.
Almmustuhtton: (2016-01-01)